MGC Pharmaceuticals (ASX:MXC)

The dominoes are falling neatly into place for those with a stake in the medical cannabis space.

With Australia now falling into line with much of the Western world in green-lighting the legal sale of marijuana products for medical use in Australia, whole new markets have opened up for those with commercial products.

For MGC Pharmaceutical (ASX: MXC), this move by the Australian government opens up several commercial channels with regard to its medical cannabis and cosmetics plays.

Should it reach its milestone of obtaining an Australian Medical Cannabis licence, we could see MXC products on local shelves very soon.

MXC’s move into the Australian commercial market has been enhanced considerably after the company completed the acquisition of Panax Pharma earlier this month.

The acquisition immediately enables MXC to conduct medical breeding research starting in a 1000m 2 dedicated greenhouse growing space, with the ability to scale further.

It also means MXC is now on the fast track to commercialisation in the medical cannabis sector from its European operating base, and in Australia.

The information on this page should not be the only trigger for your investment decision. Click on the links below for a more in-depth and informed examination of the company. We strongly recommend you seek professional financial advice whenever making financial investment decisions.

With a cannabinoid extraction facility nearing completion, MXC remains on track to commence first production next quarter.

With plans to sell high-margin cannabinoids in resin form, MXC is well positioned to capture a good slice of this growing medical cannabis market.

Latest Article

MXC to Build Malta Production Facility to Capitalise on $55B Global Pot Market

MXC to Build Malta Production Facility to Capitalise on $55B Global Pot Market

MGC Pharmaceuticals (ASX:MXC) has wasted no time ramping up its game in 2018.

READ ARTICLE

Related MGC Pharmaceuticals (ASX:MXC) articles

Top Trending